Related Experiment Video

Updated: Apr 29, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K

Discoidin domain receptor 2 signaling networks and therapy in lung cancer

Leo S Payne1, Paul H Huang

  • 1Division of Cancer Biology, Institute of Cancer Research, London SW3 6JB, United Kingdom.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|May 16, 2014
PubMed

Insights

Discoidin domain receptor 2 (DDR2) mutations are found in lung squamous cell cancer. Targeting DDR2 with small molecule inhibitors may offer new lung cancer treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Discoidin domain receptor 2 (DDR2) is a receptor tyrosine kinase activated by collagen.
  • DDR2 mutations occur in 3-4% of lung squamous cell cancers.
  • DDR2's role in cancer is context-dependent, acting as both an oncogene and tumor suppressor.

Purpose of the Study:

  • To summarize current knowledge of DDR2 biology and signaling in lung squamous cell cancer.
  • To explore the dual role of DDR2 in cancer cells.
  • To identify therapeutic opportunities targeting DDR2.

Main Methods:

  • Literature review of exon sequencing studies.
  • Analysis of DDR2 signaling pathways.
  • Review of targeted small molecule inhibitors.

Main Results:

  • DDR2 mutations are identified in lung squamous cell carcinoma.
  • DDR2 exhibits context-dependent oncogenic and tumor-suppressive functions.
  • Targeted DDR2 inhibition presents a potential therapeutic strategy.

Conclusions:

  • DDR2 is a relevant target in lung squamous cell cancer.
  • Understanding DDR2's complex role is crucial for effective therapy.
  • Small molecule inhibitors offer promising treatment avenues for lung cancer patients.

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
8.6K
Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
4.7K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K